🔗 Share this article

Former Prime Minister Sunak has intensified his campaign for a targeted examination protocol for prostate gland cancer.

In a recent discussion, he expressed being "persuaded of the critical importance" of introducing such a initiative that would be economical, achievable and "save innumerable lives".

His statements come as the National Screening Advisory Body reconsiders its ruling from five years ago against recommending routine screening.

Media reports propose the body may uphold its current stance.

Athlete Adds Voice to Campaign

Champion athlete Sir Hoy, who has late-stage prostate cancer, wants younger men to be checked.

He proposes lowering the age threshold for requesting a PSA blood screening.

Currently, it is not automatically provided to men without symptoms who are under 50.

The prostate-specific antigen screening is controversial though. Measurements can elevate for causes other than cancer, such as inflammation, leading to incorrect results.

Critics argue this can lead to needless interventions and adverse effects.

Targeted Testing Proposal

The suggested screening programme would concentrate on individuals in the 45-69 age bracket with a family history of prostate gland cancer and men of African descent, who face increased susceptibility.

This group encompasses around 1.3 million individuals in the Britain.

Charity estimates suggest the system would necessitate £25 million per year - or about £18 per participant - comparable to colorectal and mammary cancer screening.

The estimate involves twenty percent of qualified individuals would be notified annually, with a seventy-two percent uptake rate.

Medical testing (scans and biopsies) would need to increase by almost a quarter, with only a moderate growth in medical workforce, according to the analysis.

Medical Community Response

Various healthcare professionals are sceptical about the value of screening.

They contend there is still a possibility that patients will be medically managed for the condition when it is potentially overtreated and will then have to experience complications such as bladder issues and erectile dysfunction.

One prominent urological specialist stated that "The problem is we can often identify conditions that may not require to be treated and we risk inflicting harm...and my apprehension at the moment is that harm to benefit ratio needs adjustment."

Individual Experiences

Patient voices are also influencing the conversation.

One case features a man in his mid-sixties who, after seeking a PSA test, was identified with the disease at the age of 59 and was told it had metastasized to his hip region.

He has since undergone chemotherapy, radiation treatment and endocrine treatment but remains incurable.

The individual supports examination for those who are genetically predisposed.

"This is very important to me because of my children – they are approaching middle age – I want them screened as soon as possible. If I had been examined at fifty I am certain I wouldn't be in the circumstances I am currently," he said.

Future Steps

The Screening Advisory Body will have to assess the data and viewpoints.

Although the recent study says the consequences for staffing and accessibility of a screening programme would be achievable, opposing voices have contended that it would take scanning capacity otherwise allocated to patients being managed for alternative medical problems.

The current dialogue emphasizes the multifaceted balance between early detection and likely excessive intervention in prostate gland cancer care.